Anthropic filed an IPO document acknowledging its lack of experience in physical scientific experimentation and the protracted nature of drug development, contrasting with earlier claims from CEO Dario Amodei. Amodei previously stated that Anthropic was "open" to the idea that AI systems could produce a thousand years of progress in biology in just five to 10 years. In an August post on X, he predicted AI could enable cures for most human diseases within five to 10 years and promised a "deluge of AI-accelerated drugs."
The company's IPO filing still asserts that AI can "profoundly accelerate the rate of progress in biology and medicine" and compress "decades of scientific progress into years." However, the filing noted that the company's teams "need first-hand experience doing scientific research and drug discovery" and that its life sciences activities will require engaging in activities outside its historical experience as a software and research organization, including handling potentially hazardous materials and operating laboratory equipment. Regarding its earlier promotion of a "Crispr-like" enzyme discovery by Claude, the company toned down the language, stating the enzyme "might have the potential to be developed into a novel biotechnology tool, perhaps for gene editing."
The IPO filing indicates Anthropic views biotech discovery as a core part of its business model, recognizing that any resulting drug candidates or discoveries "would face the lengthy, costly, and uncertain development and regulatory pathways characteristic of the life sciences industry, and may never generate revenue." This contrasts with Amodei's August post, where he argued for streamlining regulations for the coming wave of AI-generated drugs.
